Clinical studies overview Search menu
  1. Home
  2. Clinical studies overview
  3. IMA402-101

IMA402-101

A Phase I/II Study to Evaluate the Safety, Tolerability, and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER),® in Patients With Relapsed and/or Refractory Solid Tumors

  • NKI code: M24IMA
  • Company Code: IMA402-101
  • Code clinicaltrials.gov: NCT05958121

Principal investigator

Dr. T. Schutte

Medication

IMA402; a bispecific T-Cell engager focused on PRAME

Summary

This study will look at the safety, tolerability, and anti-tumor activity of the investigational novel drug IMA402. IMA402 is being tested at different doses in patients with advanced or metastatic cancer who are no longer responding to standard treatments.

Read more on clinicaltrials.gov.

Notes

  • Dose-escalation: melanoma – open
  • Dose-escalation: endometrium – open
  • Dose-escalation: ovary – closed
onload

Disclaimer

This translation was generated automatically based on information in Dutch. It has not been reviewed by a medical specialist. The purpose of this translation is to make our information accessible to non-Dutch speakers. However, this information should not be considered a substitute for medical advice from your treating physician. The Netherlands Cancer Institute cannot guarantee the accuracy of this translation. For medical questions or advice, please consult your physician.

This website uses cookies

The NKI Centre for Early Clinical Studies places functional cookies and analytical cookies with very little or no privacy impact, unless you give permission for other cookies (as shown below). More information can be found in our cookie statement at the bottom of this page.

Functional and analytical
[1]
  • A working website
    By placing this cookie, we can offer you a functional website and we as an organization receive anonymized website statistics.
Media
[1]
  • YouTube
    This allows you to watch the videos on our website

Cookie Information

Accept cookies!